Drugs / I10E
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02317562 | Nov 2015 → Jul 2017 | chronic inflammatory demyelinating polyradiculoneuropathy | LFB | Terminated | No outcome recorded |
| Phase 3 | NCT02293460 | May 2015 → Sep 2017 | chronic inflammatory demyelinating polyradiculoneuropathy | LFB | Completed | No outcome recorded |
| Phase 3 | NCT01951924 | Dec 2013 → Jul 2016 | motor neuron disorder | LFB | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | I10E | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02317562 ↗ |
| Known as | Human normal Immunoglobulin | “Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)” NCT01951924 ↗ |
| Modality | Protein / enzyme biologic | “Human normal Immunoglobulin” NCT01951924 ↗ |
| Route | Intravenous | “intravenous administration” NCT01951924 ↗ |